Precipio(PRPO)2024-11-18 23:16Financial Data and Key Metrics - The company crossed the 10,000 case mark for the year, compared to close to 8,000 in 2023 [7] - Q3 pathology revenues reached 680,000 [13] - Cash burn reduced by 75% from approximately 226,000 in Q3 2024 [19] Business Line Performance - Pathology division exceeded breakeven for the second consecutive quarter, with a goal to reach a $20 million run rate [9] - Products division is progressing towards breakeven, with three key customers in onboarding stages expected to significantly impact performance [13] - Products division is expected to become the main growth engine due to recurring revenue, customer retention, and higher margins [14][15] Market and Strategic Direction - The company aims to achieve breakeven in 2024, avoiding dilutive capital raises and focusing on organic growth [8] - Pathology division serves as a self-sustained cost-free R&D platform, supporting future product development [10] - The company plans to leverage distribution channels for product sales, increasing revenue share from distributors [17][18] Management Commentary on Environment and Outlook - Management is confident in achieving financial independence and building cash reserves through organic growth [20][21] - The company plans to enhance investor education and visibility through investor conferences, analyst coverage, and consistent performance [25][26] - Management anticipates ending the year strong and entering the next year with even stronger performance [27] Other Important Information - The company’s sales team consists of five members in the pathology division and three in the products division, with potential hiring for additional stability [11][16] - The majority of revenues are currently from direct sales, but a gradual shift towards distributor-generated revenue is expected [17] Q&A Session - No specific questions or answers were provided in the transcript [31]